Therapy with topical corticosteroids has improved greatly in recent years due to both advanced understanding of their mode of action and awareness of their side effects, as well as newly developed derivatives with specifically designed pharmacological properties. Paradoxically, the fear of using corticosteroids has increased on the part of the public during the same period. Treatment of inflammatory or neoplastic skin disorders with topical corticosteroids can be both successful and safe only if certain points are clarified before it is begun. These include (a) specific diagnosis, (b) choice of strength of the compound needed for control of the disease, (c) time schedule for length of therapy and planned patient visits, and (d) choice of vehicle adequate to the skin lesion. Topical corticosteroids of different potency are available today; one can classify these into four groups (weak, medium, strong, very strong) and use them in a patient-tailored treatment. When large areas are to be treated, systemic side effects must be taken into consideration, and compounds that are degraded quickly after absorption are recommended. Finally, the corticophobia of many patients must be addressed by careful information to ensure compliance. Using these guidelines, treatment with corticosteroids is highly effective, easy to use by the patient, and allows a maximum of safety.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bos JD, Havu VK (1989) Topical corticosteroids today. Acta Derm Venereol (Stockh) 69 [Suppl]: 151
Flower R (1989) Lipocortin. Biochem Soc Trans 17: 276–278
Frosch PJ, Behrenbeck EM, Frosch K (1981) The Duhring chamber assay for corticosteroid atrophy. Br J Dermatol 104: 57–65
Gibson JR, Kirsch J, Darley CR (1983) An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations. Clin Exp Dermatol 8: 489–493
Gibson JR, Kirsch J, Darley CR (1989) An assessment of the relationship between vasoconstrictor assay findings, clinical efficiency and thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Dermatol 111 [Suppl 27]: 204–212
Greaves MW, Camp RDR (1988) Prostaglandis, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin. Arch Dermatol Res 280: 533–541
Harding SM, Sohail S, Busse MJ (1985) Percutaneous absorption of clobetasol propionate from novel ointment and cream foundations. Clin Exp Dermatol 10: 13–21
Polano MK, Ponec M (1976) Dependence of corticosteroid penetration on the vehicle. Arch Dermatol 112: 675–680
Ryatt KS, Feather JW, Mehta A et al. (1982) The stability and blanching efficacy of betametasone-17-valerate in emulsifying ointment. Br J Dermatol 107: 71–76
Solito E, Parente L (1989) Modulation of phospholipase A2 activity in human fibroblasts. Br J Pharmacol 96: 656–660
About this article
Cite this article
Sterry, W. Therapy with topical corticosteroids. Arch Dermatol Res 284, S27–S29 (1992). https://doi.org/10.1007/BF00638237
- Topical therapy
- Skin disorders
- Systemic side effects